Profile data is unavailable for this security.
About the company
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-111.68m
- Incorporated2018
- Employees60.00
- LocationTyra Biosciences Inc2656 State StreetCARLSBAD 92008United StatesUSA
- Phone+1 (619) 728-4760
- Fax+1 (302) 655-5049
- Websitehttps://tyra.bio/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | 0.00 | -149.28m | 1.56bn | 123.00 | -- | 4.92 | -- | -- | -1.80 | -1.80 | 0.00 | 3.02 | 0.00 | -- | -- | 0.00 | -48.67 | -51.56 | -55.94 | -60.70 | -- | -- | -- | -118.26 | -- | -- | 0.00 | -- | -77.06 | 127.75 | -712.42 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 599.82m | -8.78m | 1.56bn | 580.00 | -- | -- | -- | 2.71 | -0.0473 | -0.0473 | 2.78 | -1.84 | 1.28 | 2.10 | 7.32 | 1,034,166.00 | -1.87 | -40.01 | -2.96 | -53.68 | 97.39 | 97.34 | -1.46 | -75.69 | 1.83 | 0.9698 | 2.35 | -- | 36.00 | 55.97 | 60.77 | -- | 26.79 | -- |
| Agios Pharmaceuticals Inc | 44.79m | -401.27m | 1.57bn | 486.00 | -- | 1.23 | -- | 35.32 | -6.96 | -6.96 | 0.7768 | 22.04 | 0.0282 | 0.1959 | 11.00 | 92,162.55 | -25.26 | -10.38 | -26.90 | -11.09 | 87.22 | -- | -895.86 | -768.40 | 13.39 | -- | 0.00 | -- | 36.07 | -- | 291.35 | -- | -32.66 | -- |
| Alvotech SA | 573.35m | 69.50m | 1.60bn | 1.01k | 24.85 | -- | 15.42 | 2.83 | 0.2093 | 0.2093 | 1.93 | -0.5671 | 0.434 | 1.53 | 4.30 | 567,111.80 | 5.26 | -- | 6.38 | -- | 55.59 | -- | 12.12 | -201.24 | 0.7376 | 2.57 | 1.16 | -- | 426.84 | 42.86 | 57.98 | -- | 47.91 | -- |
| Oruka Therapeutics Inc | 0.00 | -101.63m | 1.61bn | 28.00 | -- | 3.29 | -- | -- | -2.36 | -2.36 | 0.00 | 10.06 | 0.00 | -- | -- | 0.00 | -22.01 | -32.95 | -22.98 | -34.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -1,468.16 | -- | 116.21 | -- |
| Tyra Biosciences Inc | 0.00 | -111.68m | 1.63bn | 60.00 | -- | 5.97 | -- | -- | -1.88 | -1.88 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -32.73 | -24.74 | -34.14 | -25.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -25.09 | -- | 101.48 | -- |
| Sionna Therapeutics Inc | 0.00 | -70.68m | 1.64bn | 48.00 | -- | 5.25 | -- | -- | -1.61 | -1.61 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -26.35 | -- | -27.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.52 | -- | -- | -- |
| Celldex Therapeutics Inc | 2.60m | -224.53m | 1.65bn | 186.00 | -- | 2.74 | -- | 629.48 | -3.38 | -3.38 | 0.0392 | 9.01 | 0.0035 | -- | 5.52 | 13,978.49 | -30.51 | -27.70 | -32.24 | -29.29 | -- | -- | -8,635.85 | -1,912.91 | -- | -- | 0.00 | -- | 1.99 | 14.46 | -11.62 | -- | 21.29 | -- |
| MBX Biosciences Inc | 0.00 | -80.50m | 1.66bn | 43.00 | -- | 4.35 | -- | -- | -3.39 | -3.39 | 0.00 | 8.67 | 0.00 | -- | -- | 0.00 | -23.59 | -- | -24.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -90.16 | -- | -- | -- |
| Enliven Therapeutics Inc | 0.00 | -97.21m | 1.67bn | 65.00 | -- | 3.48 | -- | -- | -1.85 | -1.85 | 0.00 | 8.03 | 0.00 | -- | -- | 0.00 | -24.41 | -35.02 | -25.43 | -38.16 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.36 | -- | -20.66 | -- |
| Rapt Therapeutics Inc | 0.00 | -105.64m | 1.67bn | 60.00 | -- | 6.40 | -- | -- | -11.08 | -11.08 | 0.00 | 9.02 | 0.00 | -- | -- | 0.00 | -77.05 | -49.22 | -84.35 | -54.31 | -- | -- | -- | -4,359.44 | -- | -- | 0.00 | -- | -- | -- | -11.19 | -- | -32.77 | -- |
| Zymeworks Inc | 134.48m | -63.43m | 1.68bn | 263.00 | -- | 5.38 | -- | 12.65 | -0.8448 | -0.8448 | 1.78 | 4.23 | 0.3041 | -- | 5.07 | 480,289.30 | -14.34 | -19.80 | -16.73 | -23.38 | -- | -- | -47.16 | -80.81 | -- | -- | 0.00 | -- | 0.3842 | 20.90 | -3.39 | -- | -26.07 | -- |
| Biohaven Ltd | 0.00 | -780.11m | 1.70bn | 256.00 | -- | -- | -- | -- | -7.60 | -7.60 | 0.00 | -0.1622 | 0.00 | -- | -- | 0.00 | -169.65 | -- | -238.45 | -- | -- | -- | -- | -- | -- | -- | 1.07 | -- | -- | -- | -107.37 | -- | -- | -- |
| Definium Therapeutics Inc | 0.00 | -168.10m | 1.71bn | 74.00 | -- | 10.21 | -- | -- | -1.97 | -1.97 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -60.39 | -55.68 | -73.40 | -63.31 | -- | -- | -- | -- | -- | -- | 0.2362 | -- | -- | -- | -13.52 | -- | -- | -- |
Data as of Feb 10 2026. Currency figures normalised to Tyra Biosciences Inc's reporting currency: US Dollar USD
59.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 30 Sep 2025 | 12.20m | 22.86% |
| BVF Partners LPas of 30 Sep 2025 | 3.65m | 6.84% |
| Commodore Capital LPas of 30 Sep 2025 | 3.38m | 6.32% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 2.87m | 5.39% |
| Vestal Point Capital LPas of 30 Sep 2025 | 2.43m | 4.54% |
| Kynam Capital Management LPas of 30 Sep 2025 | 2.33m | 4.37% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 1.66m | 3.12% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.41m | 2.63% |
| Farallon Capital Management LLCas of 30 Sep 2025 | 1.14m | 2.14% |
| Balyasny Asset Management LPas of 30 Sep 2025 | 846.59k | 1.59% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
